Kisspeptin-10

Kisspeptin-10 is a naturally occurring, short-chain neuropeptide (a 10-amino-acid sequence) produced in the brain. It serves as a master regulator of the reproductive system, stimulating the hypothalamus to release Gonadotropin-Releasing Hormone (GnRH), which triggers the production of testosterone and estrogen.

Key Benefits

• May support natural reproductive hormone signaling and regulation
• Commonly researched for stimulating luteinizing hormone (LH) and gonadotropin release
• May help support fertility and healthy reproductive function
• Research suggests potential benefits for testosterone production and endocrine system health

FDA-Approved Uses

Conditions under clinical research

1. Hypothalamic amenorrhea (HA): Loss of menstrual cycles due to hypothalamic GnRH suppression (e.g., stress, over-exercise, low body weight)
2. [Most clinically validated use — multiple human RCTs published]
3. Secondary hypogonadism in men: Low testosterone due to hypothalamic/pituitary failure rather than testicular failure
4. Female fertility / ovulation induction: Pulsatile GnRH stimulation for follicle development
5. Psychosexual function: Emerging evidence for arousal-related effects via limbic kisspeptin receptors
6. Male reproductive function improvement: Testosterone, LH, FSH restoration
7. Polycystic ovary syndrome (PCOS): Investigational (with significant caution — kisspeptin drives the LH excess underlying PCOS pathology)

Trade Names in the USA and Manufacturers

Discovery history:

• Kisspeptins are products of the KISS1 gene — originally identified as a tumor metastasis suppressor gene (‘KiSS-1’)
• Kisspeptin receptor (KISS1R / GPR54) identified as the receptor
• Kisspeptin-10 is the 10-amino acid C-terminal fragment of kisspeptin (also called metastin), the most biologically potent fragment of the family
• Research groups: Imperial College London (Jayasena, Dhillo groups) have published the most comprehensive human clinical data

US availability (as of May 2026):

• Grey-market research peptide vendors: Available (‘research use only’)
• 503A compounding pharmacies: PROHIBITED (Category 2; PCAC voted against Category 1)
• Clinical trial access only for legitimate supervised human use

Molecular identity:

• Synthetic decapeptide (10 amino acids) — C-terminal fragment of kisspeptin
• Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ (amidated C-terminus)
• MW: ~1,302 Daltons (approximate)
• Half-life: ~3.8 minutes in healthy men (Jayasena et al., 2011) — EXTREMELY SHORT; among the shortest of any peptide in this document series
• Enzymatic cleavage by endopeptidases (particularly neprilysin) causes rapid in vivo degradation
• The extreme brevity of action necessitates IV infusion for sustained research protocols or very frequent SC injections

Dosage

CRITICAL: Kisspeptin-10’s half-life of ~4 minutes requires specific administration strategies.
CONTINUOUS administration rapidly desensitizes KISS1R receptors — LH surge appears briefly then ceases despite ongoing infusion.
INTERMITTENT (pulsatile) dosing is physiologically appropriate; mimics natural GnRH pulse regulation.

Clinical research protocols (human trials — IV, not SC):
IV bolus: 0.3–10 nmol/kg (range studied in Jayasena et al.)
IV infusion: Variable; 1–4 nmol/kg/min for stimulation testing
[IV infusion used in most published human clinical research]

Community/grey-market research dosing (SC — not supported by robust human data):
Typical reported: 50–300 mcg per SC injection
Frequency: 1–3x daily; pulsatile timing recommended
Cycle: Short cycles (1–2 weeks); then break to prevent receptor desensitization

Fertility / hypothalamic amenorrhea research:
Pulsatile IV or SC boluses designed to mimic endogenous GnRH pulse rhythm
[Clinical fertility protocols use specialist-supervised IV infusion, not self-injection]

Due to the 4-minute plasma half-life, SC administration produces a much shorter and lower-amplitude LH pulse than IV bolus. Systemic exposure varies significantly between routes — adding to dosing uncertainty for community protocols.

Reconstitution: Lyophilized powder; Bacteriostatic Water; store at -20°C; stable 7–14 days reconstituted at 4°C.

Pricing

For context on market alternatives for Kisspeptin-10, research-grade suppliers typically list pricing based on the quantity (milligrams). Standard industry pricing for 1 mg typically ranges between $75 and $100, while 5 mg quantities generally range from $180 to $205, depending on the supplier’s purity guarantees and manufacturing standards.

Tips

• The October 2024 PCAC voted AGAINST Category 1 for Kisspeptin-10. This is a more negative regulatory signal than most peptides in this document series. 503A compounding remains PROHIBITED as of May 2026.
• The pro-atherosclerotic signals observed in animal studies — while their human relevance is unclear — are a real concern that contributed to the PCAC’s negative vote.
• The 4-MINUTE PLASMA HALF-LIFE is a defining pharmacological challenge. This means: (a) SC injection produces a brief pulse with limited systemic effect; (b) continuous use rapidly desensitizes receptors; (c) reliable clinical use requires IV infusion under clinical supervision — not self-injection protocols.
• PCOS patients should AVOID kisspeptin-10: The kisspeptin → GnRH → LH cascade is already overactive in PCOS. Stimulating it further could worsen androgen excess and symptom severity.
• For hypothalamic amenorrhea: Kisspeptin-10 has the strongest human evidence of any peptide in this document series for a specific reproductive indication (multiple published RCTs from Imperial College London). If pursuing this application, do so through a specialist reproductive endocrinologist in a clinical research setting — not self-injection.
• If HPG axis stimulation is the goal for hypogonadism: Gonadorelin (Category 1, legally compoundable) achieves the same downstream GnRH stimulation with a better-established safety/regulatory profile.

Side Effects

From FDA PCAC briefing document (October 2024) and published human research:

From published human clinical studies (Jayasena et al., Imperial College London):
– Generally well-tolerated at doses studied
– Vital signs (BP, heart rate, oxygenation, liver function, renal function, electrolytes) remained stable across study periods
– No serious adverse events reported in published human studies

Commonly reported:
– Injection site reactions: Mild irritation, redness, discomfort (SC administration)
– Hot flushes: Reported — likely related to downstream LH and sex hormone surges
– Headache: Mild; reported in some participants
– Altered metabolism: One study found mice injected with pharmacological doses experienced suppressed food intake, meal size, and eating rate (appetite suppression effect — mechanism unclear)

FDA-cited safety concerns (October 2024 PCAC):
– Immunogenicity: FDA expressed specific concern about antibody formation against Kisspeptin-10 due to longer chain length (10 AA), potential impurities, and aggregates — particularly with SC/IM injection routes
– Pro-atherosclerotic signals: Animal studies demonstrated concerning vascular effects; clinical relevance in humans not established but flagged as insufficient data to dismiss
– Rapid receptor desensitization (tachyphylaxis): Continuous IV infusion in monkeys produced an initial LH surge that lasted only 3 hours before LH returned to baseline despite ongoing infusion — limits therapeutic utility with continuous dosing

Contraindications

Per FDA PCAC briefing (October 2024) and pharmacology data:

FDA-cited contraindication concerns:
– Immunogenicity risk (injectable routes): Antibody formation against KP-10 may reduce efficacy over time or cause immune reactions
– Continuous dosing: ABSOLUTE AVOIDANCE — causes rapid KISS1R receptor desensitization (tachyphylaxis); LH response disappears within hours of sustained infusion
– Pulsatile dosing ONLY for any sustained reproductive effect

Based on pharmacology:
– Hormone-sensitive cancers: Kisspeptin drives LH and sex hormone production — contraindicated in estrogen-sensitive breast cancer, prostate cancer, or other hormone-dependent malignancies
– PCOS (polycystic ovary syndrome): Kisspeptin/GnRH/LH axis is already hyperactive in PCOS — stimulation may worsen androgen excess and metabolic features
– Precocious puberty: KISS1 activating mutations cause precocious puberty — exogenous kisspeptin contraindicated in children with or at risk of early puberty
– Pregnancy: Kisspeptin plays a complex role in pregnancy; exogenous administration not recommended
– Hypersensitivity to kisspeptin-10 or components
– Cardiovascular disease: Pro-atherosclerotic animal signals warrant caution in patients with established CVD

Pharmacology

Kisspeptin-10 (KP-10) is the 10-amino acid C-terminal fragment of kisspeptin (also called metastin), the 54-amino acid peptide product of the KISS1 gene. It is the most potent bioactive fragment of the kisspeptin family. Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ (C-terminal amide). MW ~1,302 Daltons.

Physiological role of endogenous kisspeptin:
– Master regulator of the hypothalamic-pituitary-gonadal (HPG) axis
– Produced by Kiss1 neurons in the arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) of the hypothalamus
– Controls GnRH pulse generation — the fundamental driver of reproductive function

Critical pharmacokinetic limitation:
– Plasma half-life: ~3.8 minutes (±0.3 min) in healthy men (Jayasena et al., 2011)
– Rapidly degraded by endopeptidases, particularly neprilysin (NEP/CD10)
– This extreme brevity necessitates IV infusion for sustained research effect or very frequent SC injections
– Multiple research groups are developing enzymatically stable kisspeptin analogues (longer-acting) to overcome this limitation

The KISS1 gene was originally named for Hershey, Pennsylvania (where it was identified) and for ‘KiSS-1’ as a melanoma metastasis suppressor. The peptide products were subsequently identified as the endogenous ligands of the orphan receptor GPR54, later renamed KISS1R.

Mechanism of action

Kisspeptin-10 binds the kisspeptin receptor (KISS1R; also known as GPR54, AXOR12, hOT7T175) — a G-protein coupled receptor (Gq/11) expressed on GnRH neurons in the hypothalamic arcuate nucleus and AVPV:

1. GnRH Pulse Generation (primary mechanism):
KISS1R activation → Gq/11 signaling → phospholipase C → IP3/DAG → intracellular Ca²⁺ rise → GnRH release from hypothalamic neurons → pulsatile GnRH enters portal blood → reaches anterior pituitary.

2. LH and FSH Secretion:
Pituitary GnRH receptor activation → LH and FSH release into systemic circulation
→ LH: Stimulates testosterone production in men (Leydig cells) and ovulation/progesterone in women (luteal phase)
→ FSH: Stimulates sperm production (men) and follicle development (women)

3. Sex Hormone Downstream Effects:
Increased LH/FSH → increased testosterone (men) / estradiol + progesterone (women)
→ Restoration of normal reproductive axis signaling in hypogonadism / hypothalamic amenorrhea

4. Receptor Desensitization Mechanism:
Continuous KISS1R activation → receptor internalization → tachyphylaxis
→ LH surge appears initially then disappears despite ongoing kisspeptin infusion
→ Pulsatile (intermittent) dosing is physiologically correct and prevents desensitization

5. Limbic Effects (emerging research):
KISS1R expression in limbic structures (amygdala, hippocampus)
→ Possible role in sexual arousal and reward processing independent of HPG axis hormones
→ Preliminary human data: Kisspeptin infusion enhanced brain activity in limbic regions associated with sexual processing (Dhillo group, 2017)

Result Claims from Different Companies

Imperial College London research group (Jayasena, Dhillo, Badawy et al.):

Hypothalamic Amenorrhea (most robust human data):
– Jayasena et al. (2009, J Clin Endocrinol Metab): SC kisspeptin-10 robustly stimulated LH in women with HA, demonstrating an intact pituitary response to GnRH stimulation via kisspeptin
– Jayasena et al. (2014): Two-week SC kisspeptin-10 in women with HA restored menstrual cyclicity — ovulation induced in 53% of participants
– This represents the most promising human application with multiple published RCTs

Male Hypogonadism:
– Kisspeptin-10 IV infusion significantly increased LH and testosterone in men with secondary hypogonadism in multiple research studies

Male Sexual Function:
– Human neuroimaging study (Dhillo group, 2017): Kisspeptin infusion activated limbic brain regions during visual sexual stimuli — suggesting a role in sexual arousal independent of testosterone

FDA PCAC briefing assessment (October 2024):
– Acknowledged the human pharmacodynamic data showing LH stimulation is robust
– Concluded: Despite promising reproductive pharmacology, insufficient manufacturing characterization, immunogenicity data, and toxicology data to recommend Category 1 compounding authorization
– The PCAC’s negative vote reflects regulatory caution, not absence of biological activity

Disclaimer

This content about “Kisspeptin-10” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.